NYB (NYB Holdings) General and Admin. Expense: $ Mil (TTM As of Sep. 2025)


What is NYB Holdings General and Admin. Expense?

NYB Holdings NYB General and Admin. Expense is $ Mil as of Sep. 2025.

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. NYB Holdings's General and Admin. Expense for the six months ended in Sep. 2025 was $3.20 Mil. NYB Holdings does not have enough years/quarters to calculate the General and Admin. Expense for the trailing twelve months (TTM) ended in Sep. 2025.

NYB Holdings General and Admin. Expense Related Terms

NYB Holdings General and Admin. Expense Historical Data

* Premium members only.

The historical data trend for NYB Holdings's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NYB Holdings General and Admin. Expense Chart

NYB Holdings Annual Data
Trend Sep24 Sep25
General and Admin. Expense
0.43 3.20

NYB Holdings Semi-Annual Data
Sep24 Sep25
General and Admin. Expense 0.43 3.20

NYB Holdings General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

What does a General and Admin. Expense of $ Mil mean?
NYB Holdings (NYB) has a General and Admin. Expense of $ Mil as of Sep. 2025. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on NYB Holdings and its competitors.
Is NYB Holdings' General and Admin. Expense too high?
NYB Holdings' current General and Admin. Expense is $ Mil.
How does NYB Holdings' General and Admin. Expense compare to ?
NYB Holdings' General and Admin. Expense of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good General and Admin. Expense for a Biotechnology company?
A good General and Admin. Expense depends on the Biotechnology industry context. However, General and Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high General and Admin. Expense mean?
A high General and Admin. Expense can signal that a stock is expensive relative to its fundamentals. General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. View historical data on NYB Holdings and its competitors. NYB Holdings's current General and Admin. Expense is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NYB Holdings stock overvalued right now?
NYB Holdings (NYB) has a current General and Admin. Expense of $ Mil. The current General and Admin. Expense is $ Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is General and Admin. Expense calculated?
General and Admin. Expense is calculated from a company's financial statements. For NYB Holdings (NYB), the current General and Admin. Expense is $ Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

NYB Holdings Business Description

Comparable Companies
Address 456 Alexandra Road, No. 04-07, Fragrance Empire Building, Singapore, SGP, 119962
NYB Holdings Ltd, along with its subsidiaries, is a pre-clinical biopharmaceutical company engaged in the research and development of therapeutics and nutraceuticals derived from biodiversity, including tropical medicinal plants with a history of traditional use. It focuses on discovering and developing natural compounds for applications in oncology and other chronic diseases, and also offers a consumer nutraceutical product line.